Karen Bernstein, Director at Ovid Therapeutics Inc. (OVID), bought 10,000 shares at $2.02 ($20K) on 2019-02-26, disclosed to the SEC on 2019-02-28.
Open-market purchase of $20k OVID by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Clearly above the average filing.